Начало・Списък с акции・Cytokinetics Inc

Cytokinetics Inc

Отворен

СекторЗдравеопазване

77.12 -4.14

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

77.13

Максимум

79.99

Ключови измерители
By Trading Economics
Приходи	-23M -206M
Продажби	1.6M 19M
EPS	-1.67
Марж на печалбата	-1,064.485
Служители	673
EBITDA	11M -169M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+36.53% upside

Дивиденти
By Acuity
Следващи печалби	6.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	2.7B 11B
Предишно отваряне	81.26
Предишно затваряне	77.12

Настроения в новините

By Acuity

50%

162 / 340 Класиране в Healthcare

Cytokinetics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

30.07.2026 г., 18:46 ч. UTC

Event

News

Social Media

Cytokinetics receives UK marketing authorization for MYQORZO, a treatment for obstructive hypertrophic cardiomyopathy. Shares are trading higher amid positive market sentiment.

29.07.2026 г., 20:41 ч. UTC

Cytokinetics Inc shares are lower in after-market hours, influenced by a broader market decline amid rising crude oil prices and anticipation of the Fed's policy announcement.

28.07.2026 г., 19:06 ч. UTC

News

Cytokinetics shares are lower amid investor concerns over CEO Robert I. Blum's recent stock option exercise and sale, reported earlier today.

27.07.2026 г., 19:56 ч. UTC

Social Media

Cytokinetics Inc shares are lower, continuing a recent decline, amid social media discussions of a $103 price target and anticipated Myqorzo earnings in 2026.

24.07.2026 г., 23:46 ч. UTC

Cytokinetics Inc shares are lower in after-market hours, continuing recent weakness after three consecutive daily declines. No specific news was identified for the move.

22.07.2026 г., 23:16 ч. UTC

Cytokinetics Inc shares are lower in after-market hours amid broader market weakness, with no specific news identified to explain the decline.

21.07.2026 г., 18:16 ч. UTC

Cytokinetics Inc is trading higher, with no specific news identified. The stock has gained since Monday amid rising commodity prices, particularly copper and oil.

20.07.2026 г., 19:22 ч. UTC

News

Social Media

Cytokinetics shares are lower amid declines in the Biotechnology sector. Myqorzo revenue expectations exceed consensus, with a long-term projection of $1.67 billion by 2030.

Сравнение с други в отрасъла

Ценова промяна

Cytokinetics Inc Прогноза

Ценова цел

By TipRanks

36.53% нагоре

12-месечна прогноза

Среден 109.8 USD 36.53%

Висок 146 USD

Нисък 83 USD

Според 16 анализатори от Wall Street, предложили 12-месечна ценова цел за Cytokinetics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

16 ratings

Купи

Задържане

Продай

Според 16 анализатори, дали борсови рейтинги на Cytokinetics Inc през последните 3 месеца.

Настроение

By Acuity

162 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.